Cornelia Adlhoch

Cornelia Adlhoch

Auto-generated profile, based on publicly available information

Cornelia Adlhoch

European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2011 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
UBUdo Buchholz
Udo Buchholz
HBHelen Bernard
Helen Bernard
DWDirk Werber
Dirk Werber
MBMerle M. Böhmer
Merle M. Böhmer
CRCornelius Remschmidt
Cornelius Remschmidt
MKMichael Kühne
Michael Kühne
A large outbreak of the hemolytic–uremic syndrome caused by Shiga-toxin–producing Escherichia coli O104:H4 occurred in Germany in May 2011. The source of infection was undetermined.

22 April 2021 in Eurosurveillance
Verified
Journal Article
Open access
TFTjede Funk
Tjede Funk
APAnastasia Pharris
Anastasia Pharris
GSGianfranco Spiteri
Gianfranco Spiteri
NBNick Bundle
Nick Bundle
AMAngeliki Melidou
Angeliki Melidou
OGon behalf of COVID study groups
on behalf of COVID study groups
We compared 19,207 cases of SARS-CoV-2 variant B.1.1.7/S gene target failure (SGTF), 436 B.1.351 and 352 P.1 to non-variant cases reported by seven European countries. COVID-19 cases with these variants had significantly higher adjusted odds ratios for hospitalisation (B.1.1.7/SGTF: 1.7, 95% confidence interval (CI): 1.0–2.9; B.1.351: 3.6, 95% CI: 2.1–6.2; P.1: 2.6, 95% CI: 1.4–4.8) and B.1.1.7/SGTF and P.1 cases also for intensive care admission (B.1.1.7/SGTF: 2.3, 95% CI: 1.4–3.5; P.1: 2.2, 95% CI: 1.7–2.8).

1 September 2016 in Journal of Clinical Virology
Verified
Journal Article
Open access
CACornelia Adlhoch
Cornelia Adlhoch
AAAna Avellon
Ana Avellon
SBSally A. Baylis
Sally A. Baylis
ACAnna R. Ciccaglione
Anna R. Ciccaglione
ECElisabeth Couturier
Elisabeth Couturier
HDHarry Dalton
Harry Dalton
Hepatitis E virus (HEV) is endemic in EU/EEA countries, but the understanding of the burden of the infection in humans is inconsistent as the disease is not under EU surveillance but subject to national policies. Countries were asked to nominate experts and to complete a standardised questionnaire about the epidemiological situation and surveillance of HEV in their respective EU/EEA country. This study reviewed surveillance systems for human cases of HEV in EU/EEA countries and nominated experts assessed the epidemiology in particular examining the recent increase in the number of autochthonous cases. Surveillance systems and case definitions across EU/EEA countries were shown to be highly variable and testing algorithms were unreliable. Large increases of autochthonous cases were reported from Western EU/EEA countries with lower case numbers seen in Northern and Southern European countries. Lack of clinical awareness and variability in testing strategies might account for the observed differences in hepatitis E incidence across EU/EEA countries. Infections were predominantly caused by HEV genotype 3, the most prevalent virus type in the animal reservoirs. Discussions from the expert group supported joint working across countries to better monitor the epidemiology and possible changes in risk of virus acquisition at a European level. There was agreement to share surveillance strategies and algorithms but also importantly the collation of HEV data from human and animal populations. These data collected at a European level would serve the 'One Health' approach to better informing on human exposure to HEV.

29 June 2017 in Eurosurveillance
Verified
Journal Article
Open access
EAEsther J Aspinall
Esther J Aspinall
ECElisabeth Couturier
Elisabeth Couturier
MFMirko Faber
Mirko Faber
BSBengü Said
Bengü Said
SISamreen Ijaz
Samreen Ijaz
OEOn Behalf Of The Country Experts
On Behalf Of The Country Experts
Hepatitis E virus (HEV) is an under-recognised cause of acute hepatitis in high-income countries. The purpose of this study was to provide an overview of testing, diagnosis, surveillance activities, and data on confirmed cases in the European Union/European Economic Area (EU/EEA). A semi-structured survey was developed and sent to 31 EU/EEA countries in February 2016, 30 responded. Twenty of these countries reported that they have specific surveillance systems for HEV infection. Applied specific case definition for HEV infection varied widely across countries. The number of reported cases has increased from 514 cases per year in 2005 to 5,617 in 2015, with most infections being locally acquired. This increase could not be explained by additional countries implementing surveillance for HEV infections over time. Hospitalisations increased from less than 100 in 2005 to more than 1,100 in 2015 and 28 fatal cases were reported over the study period. EU/EEA countries are at different stages in their surveillance, testing schemes and policy response to the emergence of HEV infection in humans. The available data demonstrated a Europe-wide increase in cases. Standardised case definitions and testing policies would allow a better understanding of the epidemiology of HEV as an emerging cause of liver-related morbidity.

20 April 2017 in Eurosurveillance
Verified
Journal Article
Open access
DDDragoslav Domanović
Dragoslav Domanović
RTRichard Tedder
Richard Tedder
JBJohannes Blümel
Johannes Blümel
HZHans Zaaijer
Hans Zaaijer
PGPierre Gallian
Pierre Gallian
PHPatricia Hewitt
Patricia Hewitt
The public health implications of hepatitis E virus (HEV) in Europe have changed due to increasing numbers of hepatitis E cases and recent reports of chronic, persistent HEV infections associated with progression to cirrhosis in immunosuppressed patients. The main infectious risk for such immunosuppressed patients is exposure to undercooked infected pork products and blood transfusion. We summarised the epidemiology of HEV infections among blood donors and also outlined any strategies to prevent transfusion-transmitted HEV, in 11 European countries. In response to the threat posed by HEV and related public and political concerns, most of the observed countries determined seroprevalence of HEV in donors and presence of HEV RNA in blood donations. France, Germany, Spain and the United Kingdom (UK) reported cases of transfusion-transmitted HEV. Ireland and the UK have already implemented HEV RNA screening of blood donations; the Netherlands will start in 2017. Germany and France perform screening for HEV RNA in several blood establishments or plasma donations intended for use in high-risk patients respectively and, with Switzerland, are considering implementing selective or universal screening nationwide. In Greece, Portugal, Italy and Spain, the blood authorities are evaluating the situation. Denmark decided not to implement the HEV screening of blood donations.

1 January 2024 in Virus Evolution
Verified
Journal Article
Open access
PDF file
AFAlice Fusaro
Alice Fusaro
BZBianca Zecchin
Bianca Zecchin
EGEdoardo Giussani
Edoardo Giussani
EPElisa Palumbo
Elisa Palumbo
MAMontserrat Agüero-García
Montserrat Agüero-García
IMIsabella Monne
Isabella Monne
Since 2016, A(H5Nx) high pathogenic avian influenza (HPAI) virus of clade 2.3.4.4b has become one of the most serious global threats not only to wild and domestic birds, but also to public health. In recent years, important changes in the ecology, epidemiology, and evolution of this virus have been reported, with an unprecedented global diffusion and variety of affected birds and mammalian species. After the two consecutive and devastating epidemic waves in Europe in 2020–2021 and 2021–2022, with the second one recognized as one of the largest epidemics recorded so far, this clade has begun to circulate endemically in European wild bird populations. This study used the complete genomes of 1,956 European HPAI A(H5Nx) viruses to investigate the virus evolution during this varying epidemiological outline. We investigated the spatiotemporal patterns of A(H5Nx) virus diffusion to/from and within Europe during the 2020–2021 and 2021–2022 epidemic waves, providing evidence of ongoing changes in transmission dynamics and disease epidemiology. We demonstrated the high genetic diversity of the circulating viruses, which have undergone frequent reassortment events, providing for the first time a complete overview and a proposed nomenclature of the multiple genotypes circulating in Europe in 2020–2022. We described the emergence of a new genotype with gull adapted genes, which offered the virus the opportunity to occupy new ecological niches, driving the disease endemicity in the European wild bird population. The high propensity of the virus for reassortment, its jumps to a progressively wider number of host species, including mammals, and the rapid acquisition of adaptive mutations make the trend of virus evolution and spread difficult to predict in this unfailing evolving scenario.